IBB — iShares Biotechnology ETF
Healthcare Ranked #123 of 458 tracked ETFs · Issued by iShares
IBB Price Performance — Growth of $10,000
Value of a $10,000 investment in IBB over time, compared with SPY. Both lines are rebased to $10,000 on the first shared date. Based on total returns — prices are adjusted for dividends and splits, so this assumes distributions were reinvested. Hover or tap the chart for exact values.
IBB Drawdown
The "underwater" chart: IBB's decline from its highest prior value at each point in time. It shows how deep past losses ran and how long the fund took to recover to break-even.
What If You'd Invested in IBB?
See what a lump sum in IBB would have grown to, with the option to add a regular monthly contribution on top. Figures use total returns — dividends are assumed reinvested.
Past performance doesn't predict future results. Assumes contributions on the first trading day of each month, no trading costs or taxes, and reinvested distributions. History is limited to the range published in the site's daily return data.
Overview
The iShares Biotechnology ETF is a healthcare-focused fund issued by iShares with $11.2 billion in assets under management. It holds an overall rank of #123 out of 458 tracked ETFs and sits at #5 of 11 within its specific category. The fund carries a B grade with a score of 70.4 out of 100, reflecting a cost structure where the 0.44% expense ratio exceeds the category median of 0.36%. Income generation is minimal, with a dividend yield of 0.17% compared to the category median of 1.05%. Concentration is notable, as the top 10 holdings comprise 54.3% of assets, led by BlackRock Funds III at 11.7%.
The fund’s price of $203.34 places it at 79.7% of its 52-week range, indicating a position near the upper end of recent trading levels. Short-term momentum has been mixed, with a 1-week decline of 3.42% contrasting against a 1-month drop of 1.92%. However, longer-term trends show acceleration, evidenced by a 6-month return of 18.33% and a 1-year gain of 35.36%. This 1-year performance significantly outpaces the category median of 19.34%. The B grade has remained unchanged over the last 35 tracked days, based on a price history spanning 3.0 years.
With a beta of 0.70, the fund has exhibited lower sensitivity to overall market movements. Annualized volatility stands at 21.91%, which is classified as moderate, while the maximum drawdown has reached -24.85%. A Sharpe ratio of 1.39 suggests that the fund has generated favorable risk-adjusted returns relative to its volatility. Liquidity is supported by an average daily volume of 1,554,695 shares, facilitating standard trading activity. These metrics collectively describe a record of moderate price fluctuation with efficient risk compensation.
AI-generated summary based on the data on this page.
IBB Top Holdings
| # | Holding | % of Net Assets | Value |
|---|---|---|---|
| 1 | BlackRock Funds III | 11.66% | $1.06B |
| 2 | Vertex Pharmaceuticals, Inc. | 8.08% | $734M |
| 3 | Amgen, Inc. | 7.83% | $711M |
| 4 | Gilead Sciences, Inc. | 6.84% | $622M |
| 5 | Regeneron Pharmaceuticals, Inc. | 4.91% | $446M |
| 6 | Argenx SE | 3.76% | $342M |
| 7 | Alnylam Pharmaceuticals, Inc. | 3.12% | $284M |
| 8 | Natera, Inc. | 2.89% | $263M |
| 9 | Revolution Medicines, Inc. | 2.78% | $253M |
| 10 | Biogen, Inc. | 2.47% | $224M |
Holdings as of 2026-06-30 per the fund's most recent SEC N-PORT-P filing. Top 10 holdings make up 54.3% of net assets — a rough gauge of concentration risk (the higher this figure, the more the fund's return depends on a handful of names). To see how IBB's holdings overlap with other ETFs you own or are considering, check the Stock Overlap tool.
Which Funds Overlap With IBB
Holding two funds that own the same companies adds cost and complexity without adding much diversification. These tracked ETFs share the most names with IBB's top 10 — VHT overlaps most, holding 2 of the same companies as IBB's top 10 (14.7% of IBB's assets).
| ETF | Name | Shared Companies | IBB Weight | Examples |
|---|---|---|---|---|
| VHT | Vanguard Health Care Index Fund ETF Shares | 2 | 14.7% | Amgen, Inc., Gilead Sciences, Inc. |
| XLV | State Street Health Care Select Sector SPDR ETF | 2 | 14.7% | Amgen, Inc., Gilead Sciences, Inc. |
| FHLC | Fidelity MSCI Health Care Index ETF | 2 | 14.7% | Amgen, Inc., Gilead Sciences, Inc. |
| IYH | iShares U.S. Healthcare ETF | 2 | 14.7% | Amgen, Inc., Gilead Sciences, Inc. |
| VB | Vanguard Morningstar Small-Cap ETF | 2 | 5.7% | Natera, Inc., Revolution Medicines, Inc. |
Compares the top 10 reported holdings of each fund, so it's a floor on true overlap — two S&P 500 trackers overlap ~100% even when only 10 names are listed. Use the Stock Overlap tool to search by individual company.
Market Backdrop
10-Year Treasury Yield: 5.27% (as of 2026-10-06) — The yield on 10-year US Treasury bonds — the standard "risk-free rate" benchmark used to contextualize this fund’s Sharpe ratio and returns.
CBOE Volatility Index (VIX): 15.01 (as of 2026-10-06) — A real-time gauge of expected S&P 500 volatility over the next 30 days — useful context for this fund’s own volatility label.
Federal Funds Rate: 3.75% (as of 2026-09-01) — The Federal Reserve’s target policy rate, which anchors short-term borrowing costs across the economy.
What IBB's Fees Cost You
IBB charges an expense ratio of 0.44% a year, deducted automatically from the fund's value. Small percentages compound into real money — adjust the figures below to see the impact on your own numbers.
Assumes a constant gross return and no additional contributions — a simplification, but it isolates exactly what the expense ratio costs. Try the full fee calculator to model contributions and compare any two funds.
IBB Dividend Income Estimator
IBB currently yields 0.17%. Enter an amount to see the income that implies, or set a monthly income target to see the investment it would take.
Based on the fund's current trailing yield, which varies with price and distributions — treat it as an estimate, not a guarantee. Yields are not adjusted for tax.
IBB Liquidity, Domicile & Tax Treatment
Liquidity: Average daily volume is 1.6M/day. Higher volume and a larger fund generally mean lower round-trip trading costs. AUM of $11.2B provides ample scale, supporting tight spreads and issuer commitment to keep the fund open.
Domicile & tax treatment: IBB is a US-domiciled, SEC-registered ('40 Act) exchange-traded fund. Dividends and capital gains distributions are reported to US investors on Form 1099-DIV, and the fund is not subject to the PFIC reporting or UCITS-specific rules that apply to Irish- or Luxembourg-domiciled funds. Non-US investors should note that US-domiciled ETFs are generally subject to 30% US withholding tax on dividends (unless reduced by treaty) and to US estate tax exposure on the position — Irish-domiciled UCITS ETFs tracking the same index often avoid both, which is why non-US residents frequently prefer the UCITS equivalent where one exists. This is general information, not tax advice — consult a tax professional for your situation.
IBB Performance History
| Period | Return |
|---|---|
| 1-Day | +0.12% |
| 1-Week | -3.42% |
| 1-Month | -1.92% |
| 3-Month | +3.05% |
| 6-Month | +18.33% |
| YTD | +20.42% |
| 1-Year | +35.36% |
| 3-Year | +69.05% |
How IBB Compares to Other Healthcare ETFs
| Rank | Grade | Ticker | Name | 1-Year | Exp. Ratio | AUM |
|---|---|---|---|---|---|---|
| #65 | B |
VHT | Vanguard Health Care Index Fund ETF Shares | +19.34% | 0.09% | $21.8B |
| #69 | B |
XLV | State Street Health Care Select Sector SPDR ETF | +19.09% | 0.08% | $43.4B |
| #97 | B |
XBI | State Street SPDR S&P Biotech ETF | +45.58% | 0.35% | $10.4B |
| #101 | B |
FHLC | Fidelity MSCI Health Care Index ETF | +19.46% | 0.084% | $3.54B |
| #123 | B |
IBB | iShares Biotechnology ETF | +35.36% | 0.44% | $11.2B |
| #169 | C |
IYH | iShares U.S. Healthcare ETF | +18.57% | 0.37% | $3.96B |
| #173 | B |
XPH | State Street SPDR S&P Pharmaceuticals ETF | +29.90% | 0.35% | $524M |
| #193 | C |
ARKG | ARK Genomic Revolution ETF | +65.04% | 0.75% | $2.22B |
| #195 | C |
PPH | VanEck Pharmaceutical ETF | +19.21% | 0.36% | $1.02B |
| #382 | D |
IHF | iShares U.S. Healthcare Providers ETF | +12.12% | 0.37% | $1.36B |
| #434 | F |
IHI | iShares U.S. Medical Devices ETF | -15.11% | 0.37% | $3.45B |